The founder and Executive Director of Arbor Ligand Binding Assay and Immunoassay Services, Mark Cameron, has been developing and validating immunoassays for 30 years.  He is experienced on platforms that include ELISA, Meso Scale Discovery (MSD), Luminex, SPARCL and Quanterix.  Mark has validated over 275 immunoassays for cell therapy trials, gene therapy trials, biologic drug development, and in basic research.  Mark commercialized the first immunoassay to measure a phosphorylated protein (p-ERK) in 2003.  Mark is widely published and has co-authored industry guidance on how to validate commercially sourced immunoassays for drug development support and how to characterize protein calibrators used as a reference standard.  Mark has held immunoassay-related leadership positions at Labcorp, Covance, MPI Research (now Charles River Labs) and Assay Designs.  While at the Cancer Center at the University of Michigan, Mark pioneered the process of large scale T cell manufacturing for clinical trials including the formulation for patient infusion and potentancy assays that characterized the final T cell product.